Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

The Naval War College Museum in Newport opened a time capsule on Friday, unveiling artifacts and items buried on its property ...

The City Manager's office says there is no record of city code that requires property owners to remove snow and ice from ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

"As a singer, few things scare me more than acid reflux," he admitted. That said, Jelly Roll doesn’t judge those who do use ...

International Community Health Services (ICHS) has launched Together We Rise, a wellness podcast with useful information ...

Ozempic and Wegovy are being linked to surprising effects on overall health. A new study finds these drugs may improve heart ...

Here are some of the major companies whose stocks moved on the week’s news.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...